Radiation plus immunotherapy: a new hope for melanoma?
NCT ID NCT01416831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatments for metastatic melanoma that has spread: high-dose Interleukin-2 (IL-2) alone versus IL-2 combined with targeted radiation (SBRT). The goal is to see if adding radiation helps shrink tumors better than IL-2 alone. The trial enrolled 44 adults with tumors that could be safely radiated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Cancer Center
Portland, Oregon, 97213, United States